C. J. Malanga

C. J. Malanga

Auto-generated profile, based on publicly available information

C. J. Malanga

University of North Carolina, Chapel Hill, United States

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2010 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
TSTerence D. Sanger
Terence D. Sanger
DCDaofen Chen
Daofen Chen
DFDarcy L. Fehlings
Darcy L. Fehlings
MHMark Hallett
Mark Hallett
ALAnthony E. Lang
Anthony E. Lang
FVFrancisco Valero‐Cuevas
Francisco Valero‐Cuevas

1 January 2015 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KWKate L. White
Kate L. White
ERElliott Robinson
Elliott Robinson
HZHu Zhu
Hu Zhu
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
PPPrabhakar R. Polepally
Prabhakar R. Polepally
BRBryan L. Roth
Bryan L. Roth
The hypothesis that functionally selective G protein–coupled receptor (GPCR) agonists may have enhanced therapeutic benefits has revitalized interest for many GPCR targets. In particular, although κ-opioid receptor (KOR) agonists are analgesic with a low risk of dependence and abuse, their use is limited by a propensity to induce sedation, motor incoordination, hallucinations, and dysphoria-like states. Several laboratories have produced a body of work suggesting that G protein–biased KOR agonists might be analgesic with fewer side effects. Although that has been an intriguing hypothesis, suitable KOR-selective and G protein–biased agonists have not been available to test this idea. Here we provide data using a G protein–biased agonist, RB-64 (22-thiocyanatosalvinorin A), which suggests that KOR-mediated G protein signaling induces analgesia and aversion, whereas β-arrestin-2 signaling may be associated with motor incoordination. Additionally, unlike unbiased KOR agonists, the G protein–biased ligand RB-64 does not induce sedation and does not have anhedonia-like actions, suggesting that a mechanism other than G protein signaling mediates these effects. Our findings provide the first evidence for a highly selective and G protein–biased tool compound for which many, but not all, of the negative side effects of KOR agonists can be minimized by creating G protein–biased KOR agonists.

5 March 2010 in Brain
Verified
Journal Article
Open access
PDF file
LTL. Timmermann
L. Timmermann
KPK. A. M. Pauls
K. A. M. Pauls
KWK. Wieland
K. Wieland
RJR. Jech
R. Jech
GKG. Kurlemann
G. Kurlemann
Selçuk PekerSelçuk Peker
Selçuk Peker
Neurodegeneration with brain iron accumulation encompasses a heterogeneous group of rare neurodegenerative disorders that are characterized by iron accumulation in the brain. Severe generalized dystonia is frequently a prominent symptom and can be very disabling, causing gait impairment, difficulty with speech and swallowing, pain and respiratory distress. Several case reports and one case series have been published concerning therapeutic outcome of pallidal deep brain stimulation in dystonia caused by neurodegeneration with brain iron degeneration, reporting mostly favourable outcomes. However, with case studies, there may be a reporting bias towards favourable outcome. Thus, we undertook this multi-centre retrospective study to gather worldwide experiences with bilateral pallidal deep brain stimulation in patients with neurodegeneration with brain iron accumulation. A total of 16 centres contributed 23 patients with confirmed neurodegeneration with brain iron accumulation and bilateral pallidal deep brain stimulation. Patient details including gender, age at onset, age at operation, genetic status, magnetic resonance imaging status, history and clinical findings were requested. Data on severity of dystonia (Burke Fahn Marsden Dystonia Rating Scale—Motor Scale, Barry Albright Dystonia Scale), disability (Burke Fahn Marsden Dystonia Rating Scale—Disability Scale), quality of life (subjective global rating from 1 to 10 obtained retrospectively from patient and caregiver) as well as data on supportive therapy, concurrent pharmacotherapy, stimulation settings, adverse events and side effects were collected. Data were collected once preoperatively and at 2–6 and 9–15 months postoperatively. The primary outcome measure was change in severity of dystonia. The mean improvement in severity of dystonia was 28.5% at 2–6 months and 25.7% at 9–15 months. At 9–15 months postoperatively, 66.7% of patients showed an improvement of 20% or more in severity of dystonia, and 31.3% showed an improvement of 20% or more in disability. Global quality of life ratings showed a median improvement of 83.3% at 9–15 months. Severity of dystonia preoperatively and disease duration predicted improvement in severity of dystonia at 2–6 months; this failed to reach significance at 9–15 months. The study confirms that dystonia in neurodegeneration with brain iron accumulation improves with bilateral pallidal deep brain stimulation, although this improvement is not as great as the benefit reported in patients with primary generalized dystonias or some other secondary dystonias. The patients with more severe dystonia seem to benefit more. A well-controlled, multi-centre prospective study is necessary to enable evidence-based therapeutic decisions and better predict therapeutic outcomes.

1 April 1998 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
SKSanjiv Kumra
Sanjiv Kumra
LJLeslie K. Jacobsen
Leslie K. Jacobsen
MLMarge Lenane
Marge Lenane
BKBarbara I. Karp
Barbara I. Karp
JFJean A. Frazier
Jean A. Frazier
JRJudith L. Rapoport
Judith L. Rapoport

1 December 2003 in Developmental Brain Research
Verified
Journal Article
Closed access
CMC.J. Malanga
C.J. Malanga
BKBarry E. Kosofsky
Barry E. Kosofsky

1 March 1999 in Clinics in Perinatology
Verified
Journal Article
Closed access
CMC.J. Malanga
C.J. Malanga
BKBarry E. Kosofsky
Barry E. Kosofsky